Anika Therapeutics Inc (NASDAQ: ANIK) has reported a loss for its third fiscal quarter (ending September 30) of $-2.03 versus a loss $-0.45 for the same period a year ago — an increase of 351%. For the latest four quarters through September 30, E.P.S. were $-6.64 compared to $-1.68 a year ago — an increase of 295%.
Recent Price Action
Anika Therapeutics Inc (NASDAQ: ANIK) stock closed at $17.11 on 10/31/24 after a major decline of -30.7%. Moreover, exceptionally high trading volume at 714% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and has declined -30.3% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, ANIK is expected to be a modest Value Builder.
Anika Therapeutics has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Anika Therapeutics has a neutral Appreciation Score of 41 and a slightly negative Power Rating of 36, resulting in the Negative Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment